• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·8086.T
Share

Nipro Corporation Stocks

¥ 1354Last Updated 27.10.2026

Issuer Rating

6/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

¥ 1.40B

¥ 1354
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nipro Corporation, along with its various subsidiaries, operates as a diversified global enterprise primarily focusing on three key sectors: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device division is responsible for the development, production, and distribution of essential healthcare equipment. This includes products for injection-infusion therapies, dialysis treatments, and solutions for diabetes and cell culture applications, alongside artificial organ-related merchandise. Within the Pharmaceutical segment, Nipro offers a range of innovative combination products, such as dual chamber bags, pre-filled syringes, and convenient half-type kits. Furthermore, it provides comprehensive contract manufacturing services for orally administered, injectable, and topical drugs, complemented by robust logistic and distribution capabilities. The Pharma Packaging division specializes in delivering a complete portfolio of pharmaceutical containers. This encompasses a wide variety of glass products, including vials, ampoules, syringes, and cartridges, alongside glass tubes and glass bulbs designed for vacuum flasks, as well as critical components like rubber plugs. Beyond these core areas, Nipro also manufactures thermostable enzymes vital for clinical chemistry applications through its 'Other business' unit. Additionally, the corporation provides business management services. Established in Osaka, Japan, in 1947, Nipro Corporation maintains a significant international presence, serving markets across Japan, the Americas, Europe, and other parts of Asia.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 8086.T is 1996 and suggests 47.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 09:01

Insiders, a competitor, a philanthropist, and an activist: Who owns shares in Anthropic?

28.10.2026 08:30

Wall Street has identified Broadcom as a major beneficiary of Anthropic's IPO. Who else stands to gain?

28.10.2026 08:01

"Too Big a Chicken": McDonald's Partners Deem the New Menu a Failure

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026